B+
Bull case
25%
Probability
Target price
$48.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
TECX
Tectonic TherapeuticCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
TECX has moved from a one-asset story toward a two-clinical-asset setup, with TX45 carrying the main upside into the 2026 APEX readout and TX2100 adding optionality after first-human dosing began in February 2026 [#8-K-2026-02-26].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +20.7.
What can break
Earlier-than-expected financing or ATM usage if burn rises or timelines extend
Momentum
66
Value
41
Sentiment
67
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $31.00 · Bull $48.00 · Bear $16.00Analysis 2026-04-15; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-08 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-08
Investment thesis
As of 2026-09-08
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-08. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $77.56
Why
Momentum66 · Δ7d -15.0
Value41 · Δ7d -0.0
Sentiment67 · Δ7d +20.7
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +20.7.
Contradictions & invalidation
- • Earlier-than-expected financing or ATM usage if burn rises or timelines extend
- • Low-coverage small-cap biotech volatility with loose peer support and concentrated pipeline exposure
- • This is still a low-coverage small-cap biotech with binary clinical risk, no approved products, and a thesis that depends heavily on upcoming TX45 and TX2100 execution; weak data or timing slippage could compress the stock quickly.
Catalyst clock
2026-12-31
TX45 APEX Phase 2 topline readout in 2026
Lead driver: Sentiment · See AI snapshot
Momentum
66
9% active weight
Current posture
7d trendSoftening
Δ7d
-15.0
Δ21d
-10.9
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
67
62% active weight
Current posture
7d trendImproving
Δ7d
+20.7
Δ21d
+15.8
Why this grade
Composite grade C. Momentum 65.5 / Value 41.2 / Sentiment 67.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-15. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$31.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$16.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$661.75M
Beta
1.59
Shares Out
19.55M
P/E (TTM) · Derived
-8.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-8.79
Rev YoY
-
EPS YoY
+9.8%
Gross Margin
-
Op Margin
-
Net Debt
-$253.11M
Current Ratio
22.29
As of 2026-09-08 • Updated nightlySource: Internal modelMethods & Data